Author + information
- Received November 18, 2019
- Revision received February 20, 2020
- Accepted March 5, 2020
- Published online August 31, 2020.
- Arianna Pregenzer-Wenzler, MDa,
- Jo Abraham, MDa,
- Kelsey Barrell, MDa,
- Tibor Kovacsovics, MDb and
- Jose Nativi-Nicolau, MDa,∗ ()
- aCardiac Amyloidosis Program, University of Utah School of Medicine, Salt Lake City, Utah
- bHuntsman Cancer Institute, Salt Lake City, Utah
- ↵∗Address for correspondence:
Dr. Jose Nativi-Nicolau, Cardiac Amyloidosis Program, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, Utah 84132.
• Biomarkers can be used for patients with light chain amyloidosis and transthyretin amyloidosis for staging and prognosis.
• Biomarkers can be used for patients with light chain amyloidosis to determine disease progression and response to therapies.
• The role of biomarkers to determine disease progression and response to therapies in patient with transthyretin amyloidosis is an active area of investigation.
Cardiac amyloidosis is a growing field, with advancements in diagnosis and management. Cardiac biomarkers are used to predict survival and to develop severity staging systems. Cardiac biomarkers are also used in clinical practice to stratify patients for treatment and to evaluate response to therapies. The current review summarizes the major clinical utility of current biomarkers in patients with cardiac amyloidosis and provides insights about future areas of investigation.
Dr. Nativi-Nicolau’s institution has received funding for clinical trials from Pfizer, Akcea and Eidos; and educational grants from Pfizer; and he is a consultant for Pfizer, Eidos, Akcea, and Alnylam. Dr. Kovacsovics has received research support from Prothena and Janssen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.
- Received November 18, 2019.
- Revision received February 20, 2020.
- Accepted March 5, 2020.
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.